JP2015505842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505842A5 JP2015505842A5 JP2014546193A JP2014546193A JP2015505842A5 JP 2015505842 A5 JP2015505842 A5 JP 2015505842A5 JP 2014546193 A JP2014546193 A JP 2014546193A JP 2014546193 A JP2014546193 A JP 2014546193A JP 2015505842 A5 JP2015505842 A5 JP 2015505842A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutically acceptable
- racemate
- enantiomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 27
- 229940002612 prodrug Drugs 0.000 claims description 27
- 239000000651 prodrug Substances 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 230000002159 abnormal effect Effects 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- -1 perhaloalkyl Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 230000001270 agonistic effect Effects 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 208000004104 gestational diabetes Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010064720 Lack of satiety Diseases 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 0 CC(C)(CC*CC(*)C*CC1)CC1C(NI)=O Chemical compound CC(C)(CC*CC(*)C*CC1)CC1C(NI)=O 0.000 description 5
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 1
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569754P | 2011-12-12 | 2011-12-12 | |
| US61/569,754 | 2011-12-12 | ||
| US201161570789P | 2011-12-14 | 2011-12-14 | |
| US61/570,789 | 2011-12-14 | ||
| US201261734300P | 2012-12-06 | 2012-12-06 | |
| US61/734,300 | 2012-12-06 | ||
| PCT/US2012/069289 WO2013090454A2 (en) | 2011-12-12 | 2012-12-12 | Novel glp-1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505842A JP2015505842A (ja) | 2015-02-26 |
| JP2015505842A5 true JP2015505842A5 (cg-RX-API-DMAC7.html) | 2016-02-04 |
| JP6061949B2 JP6061949B2 (ja) | 2017-01-18 |
Family
ID=47436261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546193A Expired - Fee Related JP6061949B2 (ja) | 2011-12-12 | 2012-12-12 | 糖尿病などの疾患の治療のためのｇｌｐ−１受容体モジュレーターとして作用する４つの環を含むカルボン酸誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8778923B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2791112B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6061949B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140107340A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104080767A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012352349B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014013925B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2857197C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2836973T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202119A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX365923B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2634896C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013090454A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| HK1222176A1 (zh) * | 2013-06-11 | 2017-06-23 | Receptos Llc | 新型glp-1受体调节剂 |
| WO2016015014A1 (en) | 2014-07-25 | 2016-01-28 | Receptos, Inc. | Novel glp-1 receptor modulators |
| KR102497644B1 (ko) * | 2014-12-10 | 2023-02-08 | 리셉토스 엘엘씨 | Glp-1 수용체 조절제 |
| CA3017797A1 (en) | 2016-03-17 | 2017-09-21 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| KR102608220B1 (ko) | 2016-05-06 | 2023-11-29 | 아이오니스 파마수티컬즈, 인코포레이티드 | Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도 |
| HUE057838T2 (hu) | 2016-06-07 | 2022-06-28 | Jacobio Pharmaceuticals Co Ltd | SHP2 inhibitorokként hasznos új heterociklusos származékok |
| SMT202400385T1 (it) | 2017-03-23 | 2024-11-15 | Jacobio Pharmaceuticals Co Ltd | Nuovi derivati eterociclici utili come inibitori di shp2 |
| EP3615524B1 (en) | 2017-04-28 | 2022-11-09 | Receptos Llc | Novel glp-1 receptor modulators |
| ES3024932T3 (en) | 2017-09-20 | 2025-06-05 | Thiogenesis Therapeutics Inc | Compounds for the treatment of cysteamine sensitive disorders |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| MX2021006034A (es) * | 2018-11-22 | 2021-09-21 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos. |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US20220193080A1 (en) * | 2019-04-11 | 2022-06-23 | University Of The Sciences | Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor |
| PE20220143A1 (es) * | 2019-04-12 | 2022-01-27 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y usos de los mismos |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CN112521501A (zh) * | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| KR20250155067A (ko) | 2019-10-25 | 2025-10-29 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| PE20221422A1 (es) * | 2019-11-15 | 2022-09-20 | Ildong Pharmaceutical Co Ltd | Agonista del receptor glp-1 y uso de este |
| UA129481C2 (uk) * | 2020-03-18 | 2025-05-07 | Елджі Кем, Лтд. | Агоніст рецептора glp-1, фармацевтична композиція, що його містить, та спосіб її отримання |
| CN117645601A (zh) * | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1062206B (it) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
| DE2423536A1 (de) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| CA2277112C (en) | 1997-01-07 | 2008-08-26 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| PL338457A1 (en) * | 1997-07-31 | 2000-11-06 | Elan Pharm Inc | Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4 |
| TR200000482T2 (tr) * | 1997-08-22 | 2000-06-21 | F. Hoffmann-La Roche Ag. | N-Aroilfenilalanin türevleri. |
| US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| BR9916027A (pt) | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
| EP1609478A1 (en) | 1999-01-14 | 2005-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptide formulations |
| WO2000045635A1 (en) * | 1999-02-08 | 2000-08-10 | Lion Bioscience Ag | Thiazole derivatives and combinatorial libraries thereof |
| DK1263745T3 (da) | 2000-03-07 | 2004-08-16 | Aventis Pharma Gmbh | Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase |
| WO2002028830A1 (en) * | 2000-09-29 | 2002-04-11 | Ajinomoto Co.,Inc. | Novel phenylalanine derivatives |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| ATE464299T1 (de) * | 2002-02-20 | 2010-04-15 | Ajinomoto Kk | Neues phenylalaninderivat |
| WO2003089410A1 (en) * | 2002-04-19 | 2003-10-30 | Kyowa Hakko Kogyo Co., Ltd. | Phenylalanine derivative |
| RU2390520C2 (ru) * | 2003-12-22 | 2010-05-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
| CN1938283A (zh) * | 2004-02-10 | 2007-03-28 | 詹森药业有限公司 | 作为α4整联蛋白拮抗剂的哒嗪酮 |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7816324B2 (en) | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| CA2688136A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| WO2011094890A1 (en) * | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| BR112013030768B1 (pt) | 2011-06-01 | 2022-12-06 | Commscope Technologies Llc | Sistema de antena distribuída |
| CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| HK1222176A1 (zh) | 2013-06-11 | 2017-06-23 | Receptos Llc | 新型glp-1受体调节剂 |
-
2012
- 2012-12-12 CN CN201280060896.1A patent/CN104080767A/zh active Pending
- 2012-12-12 BR BR112014013925-3A patent/BR112014013925B1/pt not_active IP Right Cessation
- 2012-12-12 AU AU2012352349A patent/AU2012352349B2/en not_active Ceased
- 2012-12-12 EP EP12806828.5A patent/EP2791112B1/en active Active
- 2012-12-12 CA CA2857197A patent/CA2857197C/en active Active
- 2012-12-12 HK HK15102640.3A patent/HK1202119A1/xx unknown
- 2012-12-12 ES ES12806828T patent/ES2836973T3/es active Active
- 2012-12-12 WO PCT/US2012/069289 patent/WO2013090454A2/en not_active Ceased
- 2012-12-12 JP JP2014546193A patent/JP6061949B2/ja not_active Expired - Fee Related
- 2012-12-12 KR KR1020147017945A patent/KR20140107340A/ko not_active Withdrawn
- 2012-12-12 US US13/712,624 patent/US8778923B2/en active Active
- 2012-12-12 RU RU2014128522A patent/RU2634896C2/ru active
- 2012-12-12 MX MX2014006622A patent/MX365923B/es active IP Right Grant
-
2014
- 2014-06-05 US US14/296,907 patent/US9187522B2/en not_active Expired - Fee Related